Definium Therapeutics price target raised to $75 from $70 at Oppenheimer

Definium Therapeutics (DFTX) reported that its LSD-based treatment reduced anxiety symptoms by 9.8 points on a 56-point scale, compared to 4.7 for placebo. The company's shares, already up 190% this year, rose further on the news.

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder, meeting primary and secondary endpoints. The study showed significant reduction in HAM-A scores with a 5.1-point placebo-adjusted improvement. The company plans to submit a New Drug Application in early 2027. DFTX stock rose 3.07% to $38.89 on Friday and is up 13.40% in pre-market trading.

Definium Therapeutics (DFTX) stock surged 20.7% in pre-market trading after its Phase 3 trial of DT120 ODT for generalized anxiety disorder met its primary endpoint. The company has also received FDA Breakthrough Therapy designation for DT120 in major depressive disorder. Analysts had previously assigned Buy or Strong Buy ratings, with price targets above current levels. The stock is nearing its 52-week high of $49.70, up from a low of $8.77.

Definium Therapeutics (DFTX) shares rose 20% after reporting positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The study met primary and secondary endpoints, showing a 5.1-point reduction in anxiety scores. The drug was well-tolerated, with a safety profile consistent with prior trials. The company plans to file for FDA approval in 2027.

Definium Therapeutics (DFTX) will host a webcast on September 14, 2026, to discuss topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder. The study enrolled 245 participants across 32 centers, with primary endpoints focused on changes in HAM-A and CGI-S scores. Definium Therapeutics is a Nasdaq-listed biopharmaceutical company developing psychiatric and neurological disorder treatments.

Oppenheimer maintained an 'Outperform' rating for Target Hospitality Corp (TH) and raised its price target from $24 to $27. The company's GF Value™ indicates a 144.9% overvaluation, with a GF Score™ of 66/100. TH operates in specialty rental and hospitality services, with a market cap of $2.02 billion. Analysts remain optimistic despite valuation concerns.